Matinas BioPharma Holdings, Inc. (MTNB)

+0.012 (5.18%)
Dec 8, 2023, 4:00 PM EST - Market closed

Company Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.

It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions.

The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.

In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations.

Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings logo
Country United States
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 34
CEO Jerome D. Jabbour J.D.

Contact Details

1545 Route 206 South, Suite 302
Bedminster, New Jersey 07921
United States
Phone 908-484-8805

Stock Details

Ticker Symbol MTNB
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001582554
CUSIP Number 576810105
ISIN Number US5768101058
Employer ID 46-3011414
SIC Code 2834

Key Executives

Name Position
Jerome D. Jabbour J.D. Co-Founder, Chief Executive Officer, President and Director
Dr. Theresa Matkovits Ph.D. Chief Development Officer
Dr. James J. Ferguson FACC, M.D. Chief Medical Officer
Keith A. Kucinski CPA, M.B.A. Chief Financial Officer
Dr. Hui Liu M.B.A., Ph.D. Chief Technology Officer
Dr. Raphael J. Mannino Ph.D. Chief Scientific Officer
Frank Calamusa Executive Director and Head of Manufacturing and Supply Chain
Thomas J. Hoover M.B.A. Chief Business Officer

Latest SEC Filings

Date Type Title
Nov 20, 2023 8-K Current Report
Nov 9, 2023 8-K Current Report
Nov 8, 2023 8-K Current Report
Nov 8, 2023 10-Q Quarterly Report
Nov 2, 2023 8-K Current Report
Sep 22, 2023 8-K Current Report
Sep 20, 2023 8-K Current Report
Sep 19, 2023 DEF 14A Other definitive proxy statements
Sep 8, 2023 PRE 14A Other preliminary proxy statements
Aug 9, 2023 8-K Current Report